Citations

Clear

3042 citation(s) found for "Kumar, S".

Effects of Semaglutide on BMI and Cardiometabolic Profile in Adolescents With Variants in Monogenic Obesity‐Related Genes
Salama, Mostafa, Hassan, Doha , Vairo, Filippo Pinto e, Lteif, Aida, Hentz, Roland, Olson, Ole, Pittock, Siobhán T. , Nofal, Alaa Al , Creo, Ana Pérez, Kumar, Seema, Salama, Mostafa , Salama, Mostafa , Pittock, Siobhan , Creo, Ana , Kumar, Seema , Al Nofal, Alaa , Hentz, Roland, Kumar, Seema

Mayo Clinic

Pediatric Obesity | February 11, 2026 | Volume: 21 | Issue: 2 | Pages: No page available

10.1111/ijpo.70091 | PMID 41667135 Get It

ABSTRACT Objectives To evaluate the impact of semaglutide on body mass index (BMI) and cardiometabolic markers in adolescents with obesity and genetic variants associated with monogenic or syndromic obesity. Methods A retrospective chart review was conducted in adolescents with severe obesity who underwent multigene panel testing and were treated with semaglutide. Results Twenty‐seven adolescents (mean age 15 ± 1.9 years); BMI % of the 95th percentile 158 ± 29; (70% White) were treated with semaglutide for a mean of 10 ± 4.7 months. Participants were classified into three groups: (1) Dominant or Known Risk Variants ( n = 7); (2) Carriers of Rare Variants in Recessive Genes ( n = 10); and (3) Negative or Unmatched Genetic Findings ( n = 10). All groups showed reductions in BMI, which was not different between the groups. Adolescents with dominant or known risk variants experienced a significant decrease in BMI % of the 95th percentile (−17, (IQR −26 to −10) p = 0.022) and in BMI by −9.4% ± 7% ( p = 0.035). Significant improvements in median non‐HDL cholesterol (−16 mg/dL), total cholesterol (−15 mg/dL), and HbA1c (−0.3%) were noted in children with dominant or known risk variants ( p = 0.036). Conclusions Semaglutide was associated with significant reductions in BMI and cardiometabolic markers in adolescents (majority White) with dominant or known risk variants for monogenic obesity.
Colon-Pilot: A Generative AI Tool for Automated Colonoscopy Surveillance Recommendations and 2024 ACG/ASGE Quality Benchmarking
Garg, Sushil Kumar , Mau, Brayden , Hubers, Jeffery , Arce, Victor, Hooper, Nicole, Lindquist, Jennifer, Harper, Sarah B. , Thayer, Ann B., Mukherjee, Piyush, Loufek, Brenna, Melnick, Joe , Rost, Lauren, Robbins, Steven A. , Chaudhary, Rajeev, Harper, Sarah B , Loufek, Brenna T , Rost, Lauren M , Gomes, Rahul , Chaudhary, Rajeev , Hubers, Jeffrey , Arce, Victor, Mukherjee, Piyush, Rost, Lauren M. , Gomes, Rahul

Mayo Clinic

American Journal of Gastroenterology | February 10, 2026 | Volume: 121 | Issue: 4 | Pages: 964-973

10.14309/ajg.0000000000003946 | PMID 41665228 Get It

INTRODUCTION: High-quality colonoscopy requires accurate risk stratification for surveillance per the 2020 US Multi-Society Task Force guidelines and adherence to 2024 American College of Gastroenterology/American Society for Gastrointestinal Endoscopy quality benchmarks. Both are operationally challenging in clinical practice. We developed and validated Colon-Pilot, a large language model—powered clinical decision support system using GPT-4o to automate and standardize both functions. METHODS: The system was evaluated in 2 operational modes: (i) a human-in-the-loop clinical decision support validation of surveillance recommendations for 596 colonoscopies, comparing concordance with 2020 US Multi-Society Task Force guidelines against expert consensus, and (ii) an automated administrative audit applying Colon-Pilot to 42,632 colonoscopies across the Mayo Clinic Health System to calculate 2024 American College of Gastroenterology/American Society for Gastrointestinal Endoscopy priority quality indicators. Recommendations were autogenerated unless predefined safety criteria triggered manual review. RESULTS: Colon-Pilot issued recommendations for 522 of 596 cases (87.6%) and flagged 12.4% for manual review. For automated cases, guideline-concordant accuracy was 97.5% (Cohen κ = 0.970) versus 69.7% (κ = 0.781) for original endoscopist recommendations. Discordant artificial intelligence (AI) cases (n = 13) most often recommended longer-than-appropriate intervals (62%). Applied to the enterprise data set, Colon-Pilot calculated performance exceeding 2024 targets: adenoma detection rate 49.8% (≥35%), sessile serrated lesion detection rate 17.7% (≥6%), bowel preparation adequacy 91.8% (≥90%), and cecal intubation rate 97.4% (≥95%). DISCUSSION: Colon-Pilot demonstrated high fidelity in applying surveillance guidelines and automated quality benchmarking, outperforming unassisted endoscopists in guideline adherence. By combining safety protocols with large-scale automated reporting, it offers a scalable solution for improving both efficiency and quality in colorectal cancer prevention.
AhR activation inhibits DRP1-induced mitochondrial fission in airway smooth muscle during asthma
Tandberg, Cheyenne, Kumar, Ashish, Balraj, Premanand , Thompson, Michael A, Prakash, Y S, Pabelick, Christina M, Britt, Rodney D. , Kumar, Ashish , Reza, Mohammad Irshad , Pabelick, Christina M. , Sathish, Venkatachalem

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | February 10, 2026 | Volume: 74 | Issue: 7 | Pages: 858-868

10.1093/ajrcmb/aanag019 | PMID 41738274 Get It

Abstract In asthma, pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNFα) drive excessive mitochondrial fission in ASM cells through activating dynamin-related protein 1 (DRP1). Recently, we demonstrated that aryl hydrocarbon receptor (AhR) is expressed in human ASM and is upregulated during inflammation and asthma. This study explores the role of AhR in regulating mitochondrial fission in human ASM cells under pro-inflammatory and asthmatic conditions. Primary human nonasthmatic and asthmatic ASM cells were treated with 6-formylindolo[3,2-b]carbazole (FICZ: AhR agonist), with or without TNFα. Mitochondrial morphology was assessed using MitoTracker staining. DRP1 expression was evaluated in whole-cell and mitochondrial fractions. Loss- and gain-of-function studies (AhR inhibition, knockdown, and overexpression) were performed. AhR binding on the DRP1 promoter and promoter activity were assessed by ChIP-qPCR and luciferase reporter. The effects of AhR activation on oxygen consumption rate (OCR) were analyzed using seahorse XF-Pro. AhR activation significantly inhibited TNFα- and asthma-induced mitochondrial fission in ASM cells via inhibiting DRP1 in both inactive and active forms. In contrast, AhR inhibition or knockdown aggravated mitochondrial fission, while AhR overexpression failed to prevent TNFα-induced fission without ligand activation. Mechanistically, AhR bound the DRP1 promoter and suppressed its promoter activity, consistent with a genomic mode of action, while failing to alter ERK1/2 phosphorylation. Additionally, AhR activation also reduced TNFα- and asthma-induced increase in OCR. Collectively, this study shows that AhR activation prevents mitochondrial fission by inhibiting DRP1 in ASM during inflammation and highlights AhR as a promising therapeutic target for asthma and other airway diseases associated with mitochondrial dysfunction.
Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization
Kumar, Nitish , Gomes, Pedro Lança , Jategaonkar, Gaurav, Marino, Michael J. , Miglani, Amar , Lal, Devyani, Lal, Devyani , Kumar, Nitish , Lança Gomes, Pedro , Lal, Devyani , Jategaonkar, Gaurav A.

Mayo Clinic

Laryngoscope Investigative Otolaryngology | February 10, 2026 | Volume: 11 | Issue: 1 | Pages: No page available

10.1002/lio2.70351 | PMID 41675362 Get It

ABSTRACT Objectives We evaluated the impact of teprotumumab therapy ( TT ) introduction on orbital decompression ( OD ) utilization for thyroid eye disease ( TED ) and compared rates of significant exophthalmos reduction ( SER ) and diplopia between TT and OD . Methods Newly diagnosed TED patients treated pre (2015–2020) and post teprotumumab (2020–2025) FDA approval were identified from the EHR . Utilization trends, diplopia rates, and immediate (≤ 6 weeks post‐intervention) and long‐term follow‐up SER (≥ 2 mm reduction) were studied. Results Of 406 TED patients, 53 (36.8%) underwent OD in the pre‐ TT cohort ( n = 144). Post‐teprotumumab approval ( n = 262), primary OD was performed in 29 (11.1%), of which 3 (10.3%) were subsequently placed on TT ; primary TT was used in 68/262 (25.9%) with subsequent OD performed in 9 (13.2%). The remaining patients used other treatments (corticosteroids, orbital radiation, rituximab, tocilizumab, etc.). In the overall cohort, immediate SER was achieved in 94.4% of OD versus 83.8% of TT patients ( p = 0.028), with greater median reduction in the OD group (5 vs. 4 mm; p = 0.001). At long‐term follow‐up (median 13 vs. 12 months), SER was sustained in 85.4% of OD and 62.9% of TT patients ( p = 0.042). Pre‐therapy diplopia was more prevalent in TT vs. OD patients (79.4% vs. 59.7%; p = 0.019). New‐onset posttreatment diplopia was higher in the OD group (20.7% vs. 5.9%; p = 0.008). Conclusions Rates of OD surgery declined following FDA approval of teprotumumab. OD achieved sustained and greater exophthalmos reduction but carried a higher risk of diplopia. Contemporaneous OD indications may have evolved to use in TT‐recalcitrant TED or those in need of urgent decompression. Level of Evidence 4.
Era Improvements in Age-Standardized and Conditional Survival for Acute Myeloid Leukemia: A SEER-22 Analysis, 2000–2016
Tummala, Nayanika, Lohana, Barkha, Keswani, Shiwani, Kumar, Jatender, Alhusari, Leena, Kumar, Love, Mal, Madho, Kumar, Love

Mayo Clinic

International Journal of Cancer Care and Delivery | February 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.53876/001a.129663 Get It

Temporal Trends in Hepatoblastoma Mortality and DALYs: A Comparison Between the United States and Global Estimates (2010–2023)
Mal, Madho, Keswani, Shiwani, Tummala, Nayanika, Gundakaram, Samhitha , Alhusari, Leena, Kumar, Love, Kumar, Love

Mayo Clinic

International Journal of Cancer Care and Delivery | February 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.53876/001a.129659 Get It

Ruxolitinib: A novel molecule in the management of dermatological disorders
Datta, Shreya, Chakraborty, Disha, De, Abhishek, Dhar, Sandipan, Singh, Sushil Kumar , Chakraborty, Disha , De, Abhishek

Mayo Clinic

Indian Journal of Skin Allergy | February 4, 2026 | Volume: 5 | Issue: No issue available | Pages: 34-39

10.25259/ijsa_9_2023 Get It

Ruxolitinib (RUX) cream 1.5%, a selective Janus kinase (JAK) 1 and 2 inhibitor initially developed for myelofibrosis, has emerged as a novel therapeutic agent in dermatology. It is the first topical JAK inhibitor approved by the Food and Drug Administration for atopic dermatitis (AD) and non-segmental vitiligo. This article reviews the pharmacological profile, mechanism of action, and clinical efficacy of topical RUX in immune-mediated skin conditions. RUX inhibits cytokine-induced JAK-signal transducer and activator of transcription signaling, reducing inflammation and pruritus with minimal systemic absorption and a favorable safety profile. In phase III TRuE-AD1/AD2 trials, RUX demonstrated significant improvements in the investigator’s global assessment, eczema area and severity index scores, and pruritus in patients with mild-to-moderate AD. Similarly, in the TRuE-V1/V2 studies for vitiligo, RUX achieved superior rates of facial vitiligo area scoring index (F-VASI75) and other repigmentation measures compared to vehicle, with sustained benefits at week 52. Common adverse effects included application site reactions such as burning, acne, and pruritus. Beyond its approved indications, emerging evidence supports off-label use in conditions such as lichen planus, alopecia areata, and cutaneous lupus, among others. While preliminary data suggest a positive impact on the skin microbiome, further studies are warranted. RUX cream represents a promising advancement in targeted dermatological therapy, offering localized efficacy with minimal systemic risk.
Real-world sinonasal outcomes in patients with primary diffuse chronic rhinosinusitis treated with mepolizumab across polyp phenotypes
Kumar, Nitish , Patel, Evani, Marino, Michael J. , Lal, Devyani, Kumar, Nitish

Mayo Clinic

Frontiers in Immunology | February 4, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1776180 | PMID 41716394 Get It

Background Mepolizumab blocks IL-5, targeting eosinophilic type-2 inflammation. Due to existing phenotype driven patient selection, evidence of its effectiveness in primary diffuse CRS and CRS without nasal polyps (CRSsNP) and in real-world populations is limited. Our objective was to evaluate the real-world effectiveness of mepolizumab in patients with primary diffuse CRS, regardless of nasal polyp status, and to assess outcomes across CRS phenotypes and prior surgical history. Methods Adults with primary diffuse CRS treated with mepolizumab for ≥6 months were identified. Pre- and post-therapy outcomes included serum eosinophil counts, Lund-Mackay CT scores, Lund-Kennedy endoscopic scores, and SNOT-22 symptom scores. Subgroup analyses were performed by CRS phenotype (CRSwNP vs . CRSsNP) and prior endoscopic sinus surgery (ESS). Biologic switching and discontinuation were recorded. Results Among 277 patients (mean age 60.8 ± 14.7 years; 54.9% female), 93.5% had type-2 comorbidities, 29.6% had CRSsNP, and 27.8% were ESS-naïve. The median duration of mepolizumab therapy was 31 months. Mepolizumab therapy significantly reduced serum eosinophils (median 0.57 to 0.07 ×10 9 /L, p<0.001) and Lund-Mackay scores (median 14 to 10, p<0.001), which was consistent across all subgroups. Improvements in SNOT-22 and endoscopic scores were modest and not consistently significant. CRSwNP patients were more likely to undergo ESS during therapy, but time to first post-therapy ESS was longer than in CRSsNP. There were no differences in likelihood of undergoing ESS during therapy, time to subsequent ESS, or oral corticosteroid use between prior ESS and ESS-naïve patients. Biologic switching occurred in 24.9%, and discontinuation in 16.6%, primarily due to disease recalcitrance. Conclusion Mepolizumab effectively reduced systemic eosinophilia and radiographic disease burden in primary diffuse CRS, independent of phenotype or prior ESS. Symptom improvement was variable, highlighting the heterogeneity of clinical response. These findings support an endotype-driven approach to biologic therapy and suggest that IL-5 blockade may benefit selected CRSsNP patients.
Advances in the Management of Pediatric Heart Failure: From Medical Therapy to Mechanical Support and Transplantation
Ahmad, Rimsha , Kumar, Mahesh, Khan, Saifullah, Niaz, Mahnoor, Frangaj, Kristjana , Arslan, Fatima Safi , Hussain, Syed Sadam, Maheta, Darshilkumar, Frishman, William H., Aronow, Wilbert S., Khan, Saifullah , Niaz, Mahnoor, Maheta, Darshilkumar, Frishman, William H. , Aronow, Wilbert S.

Mayo Clinic

Cardiology in Review | February 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001186 | PMID 41634903 Get It

Pediatric heart failure is a heterogeneous, high-risk clinical syndrome that differs fundamentally from adult heart failure in its etiologies, pathophysiology, and therapeutic responses. Although its absolute prevalence is lower, children experience disproportionate morbidity and mortality, with up to 40% of patients with symptomatic cardiomyopathy progressing to death or transplantation within 2 years of diagnosis. Congenital heart disease, cardiomyopathies, and genetic or metabolic disorders dominate the etiologic spectrum, while developmental differences in myocardial signaling, neurohormonal activation, and ventricular remodeling limit direct extrapolation of adult guideline-directed medical therapy. Evidence supporting pharmacologic treatment remains limited, and most therapies are symptom-modifying rather than outcome-modifying, particularly in single-ventricle physiology. Advances in mechanical circulatory support and heart transplantation have substantially improved survival, yet pose unique anatomic, physiological, and ethical challenges in children. This review synthesizes contemporary evidence across medical, device-based, and transplant therapies, highlights lesion- and age-specific considerations, and identifies critical research gaps needed to advance outcomes in pediatric heart failure.